Study record

The Mitochondrial-Derived Peptide MOTS-c Alleviates Radiation Pneumonitis via an Nrf2-Dependent Mechanism

Zhang Y, Huang J, Zhang Y et al. · Antioxidants (Basel) · 2024

AnimalMOTS-c administeredEvidence tier CAlso: Cell study (in vitro)

What this study reported

Reported that administered MOTS-c was associated with less lung tissue damage, inflammation and oxidative stress in irradiated mice and with reduced apoptosis and mitochondrial damage in mouse lung epithelial cells. The observed effects were absent in Nrf2-deficient mice.

Limitations

Single irradiation model in one mouse strain, with group sizes, sex and blinding not reported; the mechanism rests on one transcription factor and on cell lines.

Study record

Annotated fields for this study
Study modelAnimal study (in vivo)
Substance studiedMOTS-c administeredSynthetic MOTS-c was given to cells, animals or people.
Speciesmouse
System studiedC57BL/6 mice after thoracic irradiation, plus MLE-12 and primary mouse lung epithelial cells
PopulationNot reported
DesignControlled animal experiment with cell culture experiments
Sample size as reportedNot reported
Control groupirradiated mice not given MOTS-c; Nrf2-deficient mice
Route (data field only)intraperitoneal
Endpoints measuredlung histology; inflammation; oxidative stress; alveolar epithelial apoptosis; mitochondrial damage; Nrf2 levels and nuclear translocation
Pathways measuredNRF2 / antioxidant response · Oxidative stress · Apoptosis · Inflammation
Research areasLung · Mitochondrial biology
Evidence tierC — Animal in vivo
Publication typesJournal Article

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
Mammalian
Sample size
Not reported
Controls
Appropriate
Outcome validity
Surrogate
Support for its own conclusion
Moderate

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.